182 related articles for article (PubMed ID: 22935087)
1. Tandem duplication of KIT exon 11 influences the proteome of canine mast cell tumours.
Schlieben P; Meyer A; Weise C; Bondzio A; Gruber AD; Klopfleisch R
J Comp Pathol; 2013 May; 148(4):318-22. PubMed ID: 22935087
[TBL] [Abstract][Full Text] [Related]
2. Differences in the proteome of high-grade versus low-grade canine cutaneous mast cell tumours.
Schlieben P; Meyer A; Weise C; Bondzio A; Einspanier R; Gruber AD; Klopfleisch R
Vet J; 2012 Nov; 194(2):210-4. PubMed ID: 22578690
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors.
Webster JD; Kiupel M; Yuzbasiyan-Gurkan V
BMC Cancer; 2006 Apr; 6():85. PubMed ID: 16579858
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours.
Tamlin VS; Kessell AE; Mccoy RJ; Dobson EC; Smith TS; Hebart M; Brown L; Mitrovic D; Peaston AE
Aust Vet J; 2017 Oct; 95(10):386-391. PubMed ID: 28948627
[TBL] [Abstract][Full Text] [Related]
5. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study.
Takeuchi Y; Fujino Y; Watanabe M; Takahashi M; Nakagawa T; Takeuchi A; Bonkobara M; Kobayashi T; Ohno K; Uchida K; Asano K; Nishimura R; Nakayama H; Sugano S; Ohashi Y; Tsujimoto H
Vet J; 2013 Jun; 196(3):492-8. PubMed ID: 23384436
[TBL] [Abstract][Full Text] [Related]
6. All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours.
Meyer A; Gruber AD; Klopfleisch R
J Comp Pathol; 2013 Jul; 149(1):19-29. PubMed ID: 23276382
[TBL] [Abstract][Full Text] [Related]
7. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors.
Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V
Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases and vascular endothelial growth factor in canine mast cell tumours.
Giantin M; Aresu L; Benali S; Aricò A; Morello EM; Martano M; Vascellari M; Castagnaro M; Lopparelli RM; Zancanella V; Granato A; Mutinelli F; Dacasto M
J Comp Pathol; 2012 Nov; 147(4):419-29. PubMed ID: 22520817
[TBL] [Abstract][Full Text] [Related]
9. Recurrent gene mutations detected in canine mast cell tumours by next generation sequencing.
Vozdova M; Kubickova S; Pal K; Fröhlich J; Fictum P; Rubes J
Vet Comp Oncol; 2020 Dec; 18(4):509-518. PubMed ID: 31999054
[TBL] [Abstract][Full Text] [Related]
10. Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis.
Vascellari M; Giantin M; Capello K; Carminato A; Morello EM; Vercelli A; Granato A; Buracco P; Dacasto M; Mutinelli F
Vet Pathol; 2013 Jan; 50(1):110-21. PubMed ID: 22673539
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical characterization of feline mast cell tumors.
Mallett CL; Northrup NC; Saba CF; Rodriguez CO; Rassnick KM; Gieger TL; Childress MO; Howerth EW
Vet Pathol; 2013 Jan; 50(1):106-9. PubMed ID: 22492208
[TBL] [Abstract][Full Text] [Related]
12. Expression of serotonin and its 5-HT1A receptor in canine cutaneous mast cell tumours.
Fröberg GK; Lindberg R; Ritter M; Nordlind K
J Comp Pathol; 2009; 141(2-3):89-97. PubMed ID: 19446835
[TBL] [Abstract][Full Text] [Related]
13. CD25 is expressed by canine cutaneous mast cell tumors but not by cutaneous connective tissue mast cells.
Meyer A; Gruber AD; Klopfleisch R
Vet Pathol; 2012 Nov; 49(6):988-97. PubMed ID: 22446323
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of internal tandem duplications in the c-kit of dogs with multiple mast cell tumours.
Amagai Y; Tanaka A; Matsuda A; Jung K; Oida K; Nishikawa S; Jang H; Matsuda H
J Small Anim Pract; 2013 Jul; 54(7):377-80. PubMed ID: 23614673
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours.
Vozdova M; Kubickova S; Fictum P; Fröhlich J; Jelinek F; Rubes J
Vet J; 2019 May; 247():71-74. PubMed ID: 30971355
[TBL] [Abstract][Full Text] [Related]
16. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
[TBL] [Abstract][Full Text] [Related]
17. Mutation and methylation status of KIT and TP
Vozdova M; Kubickova S; Fictum P; Cernohorska H; Fröhlich J; Rubes J
Vet Comp Oncol; 2020 Sep; 18(3):438-444. PubMed ID: 31574575
[TBL] [Abstract][Full Text] [Related]
18. Expression of the KIT protein (CD117) in primary cutaneous mast cell tumors of the dog.
Preziosi R; Morini M; Sarli G
J Vet Diagn Invest; 2004 Nov; 16(6):554-61. PubMed ID: 15586571
[TBL] [Abstract][Full Text] [Related]
19. C-kit as a prognostic and therapeutic marker in canine cutaneous mast cell tumours: From laboratory to clinic.
Gil da Costa RM
Vet J; 2015 Jul; 205(1):5-10. PubMed ID: 26021891
[TBL] [Abstract][Full Text] [Related]
20. Advances in the diagnosis and management of cutaneous mast cell tumours in dogs.
Dobson JM; Scase TJ
J Small Anim Pract; 2007 Aug; 48(8):424-31. PubMed ID: 17559522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
